Klaus Urbahns' Professional Contact Details

HQ
+1 617-868-1888
Location
Boston, Massachusetts

Klaus Urbahns' Current Company Details

ProFound Therapeutics is pioneering the discovery of a vastly expanded human proteome and using its newfound insights to unlock a universe of potential new medicines. The company's ProFoundry Platform uses stat...
ProFound Therapeutics is pioneering the discovery of a vastly expanded human proteome and using its newfound insights to unlock a universe of potential new medicines. The company's ProFoundry Platform uses state-of-the-art protein detection technologies to systematically identify and validate proteins and dissect their therapeutic potential. The result is an ever-expanding database of tens of thousands of novel proteins, including their connectivity, functionality, and roles in health and disease. ProFound Therapeutics was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering.
biotechnology
expanded human proteome
first-in-class medicines
novel proteins
drug targets
high throughput screening
proteomics
translatome
functional genomics
biological insights
computational biology
rna-seq
drug discovery
therapeutic proteins
protein function prediction
clinical development
immune modulators
oncology targets
metabolic factors
genetic disease drivers
health & disease
profoundry platform
data analytics
machine learning models
protein validation
biological functions
therapeutic development
protein discovery
systematic identification
research collaboration
pioneering medicines
biopharma
genomic research
riboseq
translational research
innovative therapeutics
intervention points
therapeutic modalities
drug validation
pipeline diversification
disease intervention
biotech innovation
clinical trial readiness
early-stage therapeutics
genomic architecture
transcriptomics
biological pathways
biomedical research

Klaus Urbahns' Work History and Education

ProFound Therapeutics
Chief Scientific Officer
2023 - Present
Merck Group
Senior Director, Global Head of Medicinal Chemistry
2010 - 2023 • 13 years
EMD Serono, Inc.
Global Head, Discovery and Development Technologies
2021 - 2023 • 3 years
M Ventures
Member, Merck Ventures Investment Committee
2019 - 2023 • 4 years
AstraZeneca
Director of Medicinal Chemistry, Respiratory and Inflammation
2004 - 2010 • 6 years
Bayer
Research Scientist and Strategic Project Leader
1993 - 2004 • 11 years

Others Named Klaus Urbahns

Chief Scientific Officer at ProFound Therapeutics

Frequently Asked Questions about Klaus Urbahns


What company does Klaus Urbahns work for?

Klaus Urbahns works for ProFound Therapeutics.

What is Klaus Urbahns' role at ProFound Therapeutics?

Klaus Urbahns' role at ProFound Therapeutics is Chief Scientific Officer.

What is Klaus Urbahns' email address?

Klaus Urbahns' email address is k**@profoundtx.com.

What is Klaus Urbahns' business email address?

Klaus Urbahns' business email address is k**@profoundtx.com.

What is Klaus Urbahns' HQ phone number?

Klaus Urbahns' HQ phone number is +1 617-868-1888.

What industry does Klaus Urbahns work in?

Klaus Urbahns works in the Biotechnology industry.

Who are Klaus Urbahns' colleagues?

Klaus Urbahns' colleagues are John Lepore, Tony Manning, Denise Stevens, Haoting Jia and more.

Colleagues at ProFound Therapeutics

Chief Executive Officer
Member Board of Directors
Senior Research Associate I
Research Associate, Computational Biology

Prospect on LinkedIn

Find verified emails and direct dial mobile numbers of contacts on LinkedIn, and sync them with your CRM instantly
Download ExtensionRepresents linkedin prospector
Browse Apollo's Directories

"We love the interface, the experience, and most importantly… the results."

Erik Straub

Chief Marketing Officer, Kickfurther

"Using Apollo, we’ve solved the biggest problem for every business, the lead problem. We are now constrained by sales time and no longer lack interested prospects."

Michael Transon

CEO, Victorious

Ready to try it out?

Get started for free, then add your whole team. You can always talk to sales if you’re interested in advanced plans.